New Liver-Targeting drug could help curb alcohol cravings

NCT ID NCT05845398

Completed Disease control Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called DCR-AUD in 16 healthy adults who are social drinkers. The drug is designed to reduce the effects of alcohol by targeting the liver. The main goal was to check safety and how the body processes the drug, not to treat alcohol use disorder yet. Participants received multiple doses and had up to 10 alcohol interaction tests over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DCR-AUD (a synthetic RNA drug that targets the liver)
What this could lead to: If successful, this could lead to a new treatment that helps people with alcohol use disorder drink less by reducing the pleasurable effects of alcohol.
What could go wrong: This is a very early Phase 1 trial with only 16 healthy volunteers, not people with alcohol use disorder. It only tests safety and how the drug works in the body, not whether it actually helps reduce drinking.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER

Contacts and locations

Locations

Parexel Los Angeles Early Phase Clinical Unit

Glendale, California, 91206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.